<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220407054442N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-30</date_registration>
      <primary_sponsor>Shahre-kord University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of prophylactic effect single-dose Celecoxib and Mefenamic acid</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of prophylactic effect of single-dose Celecoxib and Mefenamic acid in reducing pain after tooth extraction</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62840</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization will be done by permutation blocks with the size of each block equal to 6. The randomization list is provided by Random Allocation software
There will be a person who is not among the collaborators of the project and does not know about the content of the interventions.
Medicines in two categories A and B are given to the patient. In addition, the patient is told that one of the two studied drugs will be given to him, but it will not be clear which of the two drugs will be given to him.
The obtained results will be presented to the statistical expert in the form of two groups A and B.
Therefore, in this study, the operator, the patient and the statistical expert are blinded, Blinding description: The patient is told that one of the two drugs celecoxib or mefenamic acid will be given at random to relieve and prevent pain after tooth extraction.
On the other hand, the assistant of the agent will randomly give one of these two drugs, which are in the same boxes and named as A and B and their type is unknown, to the patient, without informing the group type to the agent.
Reports will be given to the statistical expert in the form of two groups A and B.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Tooth extraction.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: Patients that receiving a single dose of celecoxib 200 mg capsules. Intervention 2: second intervention group: Patients receiving a single dose of Mefenamic acid 250 mg capsules.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All information of the participants, including: age, gender, type of tooth extracted, type of medication used before tooth extraction, amount of pain felt by the person, date and time of the operation, is available after the person is not identified.

When:
Access starts 6 months after the results are published.

To whom:
The data of this study is available only for researchers working in academic and scientific institutions and students studying in these centers.

Conditions:
There are the following conditions for the benefit of individuals authorized to use the information published by this study:
Be a member of researchers working in academic and scientific institutions or a student studying in these centers.
The use of the information of this study for reference as well as review studies is unimpeded.

Where to obtain:
Applicants can apply for information in the following ways:
Email to: amin1samimi@gmail.com
Refer to the research department of Shahrekord University of Medical Sciences

How to obtain:
In order to access the information of this study, the applicant should send an e-mail to amin1samimi@gmail.com and if he does not receive a response within 7 working days, he should refer to the research department of Shahrekord University of Medical Sciences to receive the information.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amin Samimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Azeen borje building, Andisheh Blvd, Farhangian Town</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8818618926</zip>
        <telephone>+98 31 3781 6798</telephone>
        <email>amin1samimi@gmail.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amin Samimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Azeen borje building, Andisheh Blvd, Farhangian Town</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8818618926</zip>
        <telephone>+98 31 3781 6798</telephone>
        <email>amin1samimi@gmail.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 14 years and of any sex who do not have a serious systemic disease and are classified in class 1 or 2 of The American Society of Anesthesiologists (ASA) will be included in this study.</inclusion_criteria>
      <agemin>14 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who referred for tooth extraction due to periodontal support problem will not be included in the study.
Patients with symptoms of infection such as swelling, fever, pus discharge, and decreased mouth opening will also not be included in the study.
Patients who need analgesics for any reason other than toothache will not be included in the study.
Patients who have a history of taking any painkillers up to 12 hours before tooth extraction will not be included in this study.
Patients with systemic physical or mental illness or at risk for infectious endocarditis, coagulation problems, local and systemic infections, known allergies to celecoxib or mefenamic acid, a history of asthma, or drug or alcohol addiction will not be included in this study.
Patients who require severe surgical intervention to extract a tooth will not be included in this study.
celecoxib is contraindicated in patients with heart problems. Therefore, patients with heart disease will not participate in this study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: Patients that receiving a single dose of celecoxib 200 mg capsules</i_keyword>
      <i_keyword>second intervention group: Patients receiving a single dose of Mefenamic acid 250 mg capsules</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score in Visual Analogue Scale score questionnaire. Timepoint: Measure the amount of pain in one, three and six hours after tooth extraction. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahre-kord University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-28</approval_date>
        <contact_name>Research Ethics Committees of Shahrekord University of Medical Sciences</contact_name>
        <contact_address>No. 9, Azeen borje building, Andisheh Blvd, Farhangian Town Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
